Health Economics›Leiomyosarcoma›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Leiomyosarcoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Doxorubicin and Trabectedin Variant #01	—	R 62 627	21d	12.1 mo	33.0 mo	18	R 1 127 278 PFS proxy	1
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	6.2 mo	—	9	R 44 207 PFS proxy	1
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	6.2 mo	—	9	R 11 639 PFS proxy	1

3 of 3 regimens shown